Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service colorectal resection cases in District of Columbia: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 271 | 24% |
| 2020 | 2 | 225 | 26% |
| 2021 | 1 | 204 | 30% |
Laparoscopic and open colectomy and proctectomy; stapler, energy, and robotics call point. Professional codes (what the surgeon bills): CPT 44204, 44205, 44207, 44140, 44145, 44160, 45395, 45397; the hospital bills MS-DRG 329, 330, 331.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in District of Columbia; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 4 | 587−0.4%/yr | −0.4%/yr | 9.81.6× | 12% | 630 in 2030+1.3%/yr |
| Cholecystectomy & appendectomy |
Colorectal resection in every state, and its device makers · Every procedure market in District of Columbia · Every state · Compare with Texas
| 2024 |
| 196 |
| 39% |
| 2025 est. | ≈ 170 | – |
| 2026 est. | ≈ 170 | – |
| 2022 | 2 | 243 | 33% |
| 2023 | 1 | 215 | 37% |
| 2024 | 1 | 196 | 39% |
| 2025 from claims | – | 169 136–198 | 41% |
| 2026 forecast | – | 171 134–215 | 40% |
| 2027 forecast | – | 171 127–226 | 41% |
| 2028 forecast | – | 172 121–237 | 42% |
| 2029 forecast | – | 172 117–246 | 42% |
| 2030 forecast | – | 172 113–256 | 43% |
In 2025, 100% inpatient hospital.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| −6.3%/yr |
| 1.7 |
| 0% |
| 3,630 in 20300%/yr |
| North Carolina | 8 | 1,589−6.5%/yr | −6.5%/yr | 1.6 | 0% | 1,360 in 2030−2.6%/yr |
| Virginia | 8 | 1,510−4.9%/yr | −4.9%/yr | 1.5 | 0% | 1,480 in 2030−0.3%/yr |
| Georgia | 9 | 1,488−6.4%/yr | −6.4%/yr | 1.8 | 0% | 1,450 in 2030−0.4%/yr |
| Tennessee | 8 | 1,264−5.6%/yr | −5.6%/yr | 1.8 | 0% | 1,230 in 2030−0.4%/yr |
| Maryland | 9 | 1,152−4.6%/yr | −4.6%/yr | 1.3 | 0% | 1,300 in 2030+2.1%/yr |
| South Carolina | 6 | 1,082−4.9%/yr | −4.9%/yr | 1.6 | 0% | 1,180 in 2030+1.5%/yr |
| Oklahoma | 7 | 875−4%/yr | −4%/yr | 1.8 | 0% | 740 in 2030−2.7%/yr |
| Kentucky | 1 | 825−7.8%/yr | −7.8%/yr | 1.8 | 0% | 700 in 2030−2.7%/yr |
| Alabama | 7 | 775−8.2%/yr | −8.2%/yr | 1.8 | 0% | 760 in 2030−0.3%/yr |
| Louisiana | 3 | 766−7.5%/yr | −7.5%/yr | 1.9 | 0% | 690 in 2030−1.6%/yr |
| Mississippi | 5 | 704−8.2%/yr | −8.2%/yr | 1.9 | 0% | 680 in 2030−0.7%/yr |
| Arkansas | 3 | 698−6%/yr | −6%/yr | 1.9 | 0% | 680 in 2030−0.3%/yr |
| West Virginia | 0 | 265−9.2%/yr | −9.2%/yr | 1.3 | 0% | 200 in 2030−4.7%/yr |
| Delaware | 2 | 264−6.1%/yr | −6.1%/yr | 1.6 | 0% | 340 in 2030+4.1%/yr |
| 4 |
| 315−2.4%/yr |
| −2.4%/yr |
| 5.11.1× |
| 2% |
| 340 in 2030+1.3%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Intuitive Surgical leads with 72% of company spending on these surgeons in 2025, +10 pts on 2024.
In 2025, 3 companies reported engagement with District of Columbia’s surgeons worth $63K in consulting, speaking, meals and travel tied to these products, about $63K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.